IVIG Market Growth is booming in next 10 years | Behring GmbH, Shanghai RAAS Blood Products Co., Ltd

Immunoglobulins (IGs) are glycoproteins produced in the blood plasma in response to antigens, which are foreign to the host system. They are highly complex entities and specific in their action. They are obtained from blood by fractionation process and purified for therapeutic and nontherapeutic applications. Different classes of immunoglobulin such as IgG, IgA, and IgM are used for the treatment of various immunological and neurological diseases.

Request Sample Report at:

https://www.alliedmarketresearch.com/request-sample/325

The major factors driving the growth of the intravenous immunoglobulin market includes significant rise in geriatric population & number of hemophilic patients, improved technologies pertaining to the immunoglobulin production, and enhanced purification techniques (with better plasma yield). Furthermore, surge in prevalence diseases such as chronic inflammatory demyelinating polyneuropathy (CIDP), hypogammaglobulinemia, and others is expected to boost the market growth. However, stringent government regulations toward the use of intravenous immunoglobulin products and high risk of side effects associated with them are expected to hamper the growth of the market. On the contrary, high adoption of intravenous immunoglobulins for the treatment of various diseases is expected to create lucrative opportunities in the near future.

Application segment review:

Based on application, the global intravenous immunoglobulin market is divided into hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy, immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura, inflammatory myopathies, specific antibody deficiency, Guillain-Barre syndrome, and others. The hypogammaglobulinemia segment was the highest contributor to the market in 2017, and is anticipated to maintain its dominance throughout the forecast period. This is attributed to the significant rise in the prevalence of hypogammaglobulinemia disorder across the globe over the years. For instance, hypogammaglobulinemia is the most common chronic immune defect in patients with lymphoproliferative disorders (LPDs). Its incidence rate is ~2 per 100,000 population yearly, globally.

Region segment review

Based on region, the intravenous immunoglobulin market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America is the largest contributor toward the global market, followed by Asia-Pacific. These regions collectively occupy almost 75% of the global market revenue. Presence of the largest plasma production facilities and high adoption rate in the developed countries majorly boost the market growth. However, LAMEA is projected to register the highest growth rate during the forecast period.

The report provides extensive competitive analysis and profiles of key market players that includes Baxter international Inc., CSL Ltd., Grifols S.A, Octapharma AG, Kedrion Biopharma Inc., LFB group, Biotest AG, China Biologics Products, Inc., Takeda Pharmaceuticals, and Bayer Healthcare.

Other players in the value chain include Hualan Biological Engineering Inc., Omrix Biopharmaceuticals Ltd., Behring GmbH, Shanghai RAAS Blood Products Co., Ltd., Option Care Enterprises, Inc., ADMA Biologics, Inc., and BioScrip, Inc.

For Purchase Enquiry at:

https://www.alliedmarketresearch.com/purchase-enquiry/325

Key Benefits for Intravenous Immunoglobulin Market:

The study provides an in-depth analysis of the global intravenous immunoglobulin market with the current trends and future estimations to elucidate the imminent investment pockets.

A comprehensive analysis of the factors that drive and restrict the market growth is provided.

A comprehensive quantitative analysis of the industry is provided from 2018 to 2025 to assist stakeholders to capitalize on the prevailing market opportunities.

An extensive analysis of the key segments of the industry helps to understand the trends in the global allergy treatment market.

Key players and their strategies are provided to understand the competitive outlook of the industry.

Contact

David Correa

1209 Orange Street,

Corporation Trust Center,

Wilmington, New Castle,

Delaware 19801 USA.

Toll Free: +1-800-792-5285

Int'l: +1-503-894-6022

UK: +44-845-528-1300

Hong Kong: +852-301-84916

India (Pune): +91-20-66346060

Fax: +1-855-550-5975

help@alliedmarketresearch.com

Web: https://www.alliedmarketresearch.com

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.